Home » Stocks » UTHR

United Therapeutics Corporation (UTHR)

Stock Price: $164.85 USD -4.50 (-2.66%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
Market Cap 7.33B
Revenue (ttm) 1.41B
Net Income (ttm) 468.60M
Shares Out 44.40M
EPS (ttm) 10.59
PE Ratio 15.57
Forward PE 13.32
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $164.85
Previous Close $169.35
Change ($) -4.50
Change (%) -2.66%
Day's Open 170.09
Day's Range 163.40 - 170.74
Day's Volume 225,618
52-Week Range 79.39 - 172.82

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 week ago

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 13, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that results from the INCREASE clinical study ...

PRNewsWire - 3 weeks ago

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 4, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief ...

PRNewsWire - 4 weeks ago

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 28, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today an agreement to acquire a Rare Pediatric Disea...

Forbes - 1 month ago

After a 63% rise since the March 23 levels of this year, at the current price of around $137 per share we believe United Therapeutics stock (NASDAQ: UTHR), a biotechnology company, has reached...

PRNewsWire - 1 month ago

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 9, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that the United States Food and Drug Administra...

Zacks Investment Research - 1 month ago

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 2 months ago

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Offic...

Seeking Alpha - 2 months ago

United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q3 2020 Results - Earnings Call Transcript

Other stocks mentioned: UAL
Zacks Investment Research - 2 months ago

United Therapeutics' (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.

Zacks Investment Research - 2 months ago

United Therapeutics (UTHR) delivered earnings and revenue surprises of 59.34% and 5.01%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for th...

Benzinga - 2 months ago

Shares of United Therapeutics (NASDAQ:UTHR) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share increased 1.31% over the past year to $3.88, which b...

PRNewsWire - 2 months ago

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended Se...

Insider Monkey - 2 months ago

Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend mi...

PRNewsWire - 3 months ago

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 22, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced new clinical data on Tyvaso® (treprostinil) In...

PRNewsWire - 3 months ago

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2020 fin...

24/7 Wall Street - 3 months ago

Earnings season is upon us and investors are pining for information about which stocks and sectors will do well.

Other stocks mentioned: ALXN, AMGN, BMRN, INSM, REGN, VRTX
PRNewsWire - 3 months ago

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it will present clinical trial data on Tyvaso®...

PRNewsWire - 4 months ago

REHOVOT, Israel and SILVER SPRING, Maryland, Sept. 21, 2020 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) and United Therapeutics Corporation (NASDAQ: UTHR) today announced an expan...

PRNewsWire - 4 months ago

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

PRNewsWire - 4 months ago

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

Zacks Investment Research - 4 months ago

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 5 months ago

United Therapeutics' (UTHR) INCREASE study evaluated Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Kiplinger - 5 months ago

It's not uncommon for stocks that have significantly outperformed for several months to take a breather.

Other stocks mentioned: ALLO, DKNG, MYOK, PLUG, XLRN, YY
PRNewsWire - 5 months ago

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

PRNewsWire - 5 months ago

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

Zacks Investment Research - 5 months ago

United Therapeutics' (UTHR) second-quarter sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.

Seeking Alpha - 5 months ago

United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

United Therapeutics (UTHR) delivered earnings and revenue surprises of 0.00% and 6.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 5 months ago

Shares of United Therapeutics (NASDAQ:UTHR) were unchanged after the company reported Q2 results.

PRNewsWire - 5 months ago

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

PRNewsWire - 6 months ago

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

Zacks Investment Research - 6 months ago

United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 6 months ago

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

InvestorPlace - 6 months ago

There’s a select group of pharmaceutical stocks that stand to win without even looking for a Covid-19 cure. The post The 7 Best Pharmaceutical Stocks That Go Beyond the Covid-19 Chase appeare...

Other stocks mentioned: ABBV, HZNP, LLY, NVO, RDY, ZTS
GuruFocus - 6 months ago

As the first half of 2020 comes to a close, investors are cautiously looking toward the remainder of the year as uncertainty surrounding the full impact the coronavirus will have on the econom...

Other stocks mentioned: ABC, BIO
PRNewsWire - 7 months ago

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 17, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that key data from the INCREASE study of Tyvas...

Zacks Investment Research - 7 months ago

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: BGS, QGEN, SPTN, VIPS
PRNewsWire - 7 months ago

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 5, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has filed a lawsuit in the U.S. Distric...

Zacks Investment Research - 7 months ago

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 7 months ago

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: BGS, QGEN, REGN, SPTN
PRNewsWire - 8 months ago

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 26, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Office...

InvestorPlace - 8 months ago

Amid the COVID-19 pandemic, the investing pros say that it’s still possible to unmask names poised to take off on an upward trajectory.

Other stocks mentioned: ARGX, ASND, AXSM, FOLD, IOVA, NTRA
Zacks Investment Research - 8 months ago

Does United Therapeutics (UTHR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 8 months ago

United Therapeutics (UTHR) beats estimates for both earnings and sales in first quarter. It expects a reduction in new patient starts in the future quarters.

Seeking Alpha - 8 months ago

United Therapeutics' (UTHR) CEO Martine Rothblatt on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

United Therapeutics (UTHR) delivered earnings and revenue surprises of 28.40% and 2.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the st...

Zacks Investment Research - 9 months ago

In the latest trading session, United Therapeutics (UTHR) closed at $93.90, marking a -0.98% move from the previous day.

Zacks Investment Research - 9 months ago

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 10 months ago

Is (UTHR) Outperforming Other Medical Stocks This Year?

Seeking Alpha - 10 months ago

United Therapeutics: Potential Promising Despite Falling Sales

About UTHR

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and internationally. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to... [Read more...]

Industry
Biotechnology
IPO Date
Jun 17, 1999
CEO
Martine Rothblatt
Employees
920
Stock Exchange
NASDAQ
Ticker Symbol
UTHR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for UTHR stock is "Buy." The 12-month stock price forecast is 173.11, which is an increase of 5.01% from the latest price.

Price Target
$173.11
(5.01% upside)
Analyst Consensus: Buy